• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Europe approves Roche’s Enspryng subcutaneous NMOSD treatment

June 28, 2021 By Sean Whooley

Roche logo - updatedRoche (SWX: RO, ROG) announced today that the European Commission approved its Enspryng subcutaneous NMOSD treatment.

Basel, Switzerland-based Roche developed Enspryng (satralizumab) to treat adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD).

Approval comes for the treatment as a monotherapy or for use in combination with immunosuppressive therapy (IST). Roche said in a news release that Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks, offering at-home dosing after appropriate training.

Enspryng demonstrated efficacy in reducing the risk of relapse in those with AQP4-IgG seropositive NMOSD over two Phase III studies, Roche added.

“We thank the NMOSD community for their partnership and are delighted that Enspryng will be available to people in the EU who until now had limited, accessible treatment options,” Roche CMO & head of global product development Dr. Levi Garraway said in the release. “Building on our growing scientific understanding of neuroimmunological conditions, we are confident ENSPRYNG can transform how people with NMOSD are treated by fitting into their day-to-day lives.”

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: European Commission, Roche

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS